SK biotek Revenue and Competitors

Fair Lawn, NJ USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • SK biotek's estimated annual revenue is currently $30.6M per year.(i)
  • SK biotek's estimated revenue per employee is $201,000

Employee Data

  • SK biotek has 152 Employees.(i)
  • SK biotek grew their employee count by -1% last year.

SK biotek's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is SK biotek?

SK biotek is a global life science company known for its presence in custom chemical development, advanced intermediates and active pharmaceutical ingredient (API) manufacturing. We have extensive experience in custom development from clinical phases to commercial manufacturing for global pharmaceutical markets. SK biotek is a life science company dedicated to service, with an eye for detailed execution, delivery and complete customer satisfaction. Driven by our desire and passion in the area of pharmaceuticals, we provide development and manufacturing capabilities with our unique technologies and expertise to accelerate our customers’ therapeutics into markets across the world. With over 20 years of company growth and constant innovation, we have developed improved processes to manufacture API in a cost efficient manner. Swords Campus is the home to SK biotek Ireland and has been manufacturing API for over 50 years. We are a world leader in continuous flow processes from development to commercial manufacturing.

keywords:N/A

N/A

Total Funding

152

Number of Employees

$30.6M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$56.8M1615%N/A
#2
$43.6M2174%N/A
#3
$44.6M2258%N/A
#4
$48.1M2437%N/A
#5
$70.6M3514%N/A